Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (LLY) is considering testing its blockbuster weight-loss drugs in individuals who are not yet overweight but are at risk of weight gain, according to an exclusive Financial Times report.

Eli Lilly (LLY) stock is soaring Thursday after the ... driven by demand for its weight-loss drugs, Mounjaro and Zepbound, as well as its breast cancer drug Verzenio. Its earnings per share ...

Eli Lilly's (LLY.N), opens new tab high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the ...

VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, designed to ...

The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly (NYSE: LLY) and Novo Nordisk ... with GLP-1s to possibly enhance weight loss or simply offer an alternative ...

When the FDA announced Eli Lilly's (LLY) active ingredient for diabetes drug Mounjaro and weight-loss drug Zepbound, tirzepatide, would be taken off the list on Oct. 2 after nearly two years ...

Two companies — Eli Lilly LLY and Novo Nordisk NVO — dominate the weight-loss drug market and their stocks have surged in the recent past due to soaring demand for their products. There are a ...

Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...

Weight-loss drugs such as Ozempic ... Novo Nordisk's (NVO) (DK:NOVO.B) Wegovy and Ozempic and Eli Lilly's (LLY) Mounjaro mimic the effects of a gut hormone known as GLP-1, which can help control ...